Impact of adherence to anti-tuberculous therapy on survival outcomes in patients with tuberculous arthritis.

Shih-Wen Ting, Jia-Feng Chen, Shan-Fu Yu, Chung-Yuan Hsu, Ying-Chou Chen

Abstract read

In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shih-Wen TingDepartment of Infection, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung Dist., Kaohsiung, 833, Taiwan.

Jia-Feng ChenDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung Dist., Kaohsiung City, Taiwan.

Shan-Fu YuDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung Dist., Kaohsiung City, Taiwan.

Chung-Yuan HsuDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung Dist., Kaohsiung City, Taiwan.

Ying-Chou ChenDepartment of Rheumatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung Dist., Kaohsiung City, Taiwan. r820713@ms13.hinet.net.

Funding

Kaohsiung Chang Gung Memorial Hospital CMRPG8I0461

6 · The paper itself

Abstract

aimEffective treatment of tuberculous arthritis depends on strict adherence to anti-tuberculous therapy to achieve cure and reduce mortality. This study aimed to investigate the impact of treatment adherence on mortality risk in patients with tuberculous arthritis.

methodsA retrospective cohort of 391 patients diagnosed with tuberculous arthritis between 2001 and 2016 was analyzed. Patient demographics, body mass index, co-morbidities, and treatment details were collected. Adherence was defined as treatment persistence, measured from initiation to discontinuation of anti-tuberculous therapy. Mortality outcomes were recorded, and Cox proportional hazards models were used to assess the association between adherence and mortality risk, adjusting for potential confounders.

resultsAmong 391 patients (mean age 65.9 ± 14.13 years; 42.5% female), 87 deaths occurred during follow-up. Overall adherence rate was 45.8%, significantly lower in the deceased group (31%) compared to survivors (50%, p = 0.002). Multivariate Cox regression demonstrated that adherence to anti-tuberculous therapy was independently associated with a 56% reduction in mortality risk (HR 0.44; 95% CI 0.28–0.71).

conclusionAdherence to anti-tuberculous therapy markedly decreases mortality risk in tuberculous arthritis patients. Targeted interventions to improve treatment adherence are essential to enhance clinical outcomes in this population. CLINICAL TRIAL: This is not clinical trial.

Indexed as

Antitubercular AgentsDrug MonitoringMedication AdherenceTuberculosis, OsteoarticularAgedAged, 80 and overFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesTreatment OutcomeAntitubercular AgentsAdherenceAnti-tuberculous therapyMortalityTreatment persistenceTuberculous arthritis

Identifiers

PMID41580601

DOI10.1186/s12879-025-12341-z

PMCPMC12914956

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.